{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 11 of 60', '9.6.1', 'Dosing', '26', '9.6.2', 'Missed Doses', '27', '9.7', 'Dose Modification for Toxicity', '27', '9.8', 'Study Drug Interruption and Stopping Rules', '27', '9.8.1', 'Liver Function Tests', '27', '9.8.2', 'Rash', '28', '9.9', 'Removal of Subjects', '29', '9.10 Replacement of Subjects', '29', '10 Study Drug Information and Management', '29', '10.1 Preparation and Dispensing', '30', '10.2 Packaging and Labeling', '30', '10.3 Study Drug Supply, Storage, and Handling', '30', '10.4 Drug Accountability', '30', '10.5 Disposal, Return, or Retention of Unused Drug', '31', '10.6 Compliance', '31', '10.7 Blinding and Unblinding', '31', '10.7.1 Blinding', '31', '10.7.2 Unblinding', '32', '11 Assessments', '33', '11.1 Timing of Assessments', '33', '11.2 Subject and Disease Characteristics', '33', '11.3 Pharmacodynamics: Sweat Chloride', '33', '11.4 Efficacy', '33', '11.4.1 Cystic Fibrosis Questionnaire-Revised', '33', '11.4.2', 'Spirometry', '34', '11.4.3', 'Height and Weight', '35', '11.5 Safety', '35', '11.5.1', 'Adverse Events', '35', '11.5.2', 'Clinical Laboratory Assessments', '35', '11.5.3', 'Physical Examinations and Vital Signs', '37', '11.5.4', 'Pulse Oximetry', '37', '11.5.5', 'Electrocardiograms', '37', '11.5.6', 'Ophthalmologic Examination', '38', '11.5.7', 'Contraception and Pregnancy', '38', '11.5.7.1 Contraception', '38', '11.5.7.2 Pregnancy', '40', '12 Statistical and Analytical Plans', '40', '12.1 Sample Size and Power', '40', '12.2 Analysis Sets', '41', '12.3 Statistical Analysis', '41', '12.3.1', 'General Considerations', '41', '12.3.2', 'Background Characteristics', '42', '12.3.2.1', 'Subject Disposition', '42', '12.3.2.2 Demographics and Baseline Characteristics', '42', '12.3.2.3', 'Prior and Concomitant Medications', '42', '12.3.2.4', 'Study Drug Exposure and Compliance', '43', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 12 of 60', '12.3.2.5 Important Protocol Deviations', '43', '12.3.3 Efficacy and Pharmacodynamic Analyses', '43', '12.3.3.1', 'Analysis of Primary Endpoint', '43', '12.3.3.2 Analysis of Key Secondary Endpoint', '44', '12.3.3.3', 'Analysis of Secondary Endpoint', '44', '12.3.3.4', 'Multiplicity Adjustment', '44', '12.3.4', 'Safety Analysis', '45', '12.3.4.1', 'Adverse Events', '45', '12.3.4.2', 'Clinical Laboratory Assessments', '46', '12.3.4.3', 'Electrocardiogram', '46', '12.3.4.4', 'Vital Signs', '47', '12.3.4.5', 'Pulse Oximetry', '47', '12.3.4.6', 'Physical Examination', '47', '12.3.5', 'Interim and IDMC Analyses', '47', '12.3.5.1', 'Interim Analysis', '47', '12.3.5.2', 'IDMC Analysis', '47', '13 Procedural, Ethical, Regulatory, and Administrative Considerations', '48', '13.1 Adverse Event and Serious Adverse Event Documentation, Severity Grading, and', 'Reporting', '48', '13.1.1 Adverse Events', '48', '13.1.1.1 Definition of an Adverse Event', '48', '13.1.1.2 Clinically Significant Assessments', '48', '13.1.1.3', 'Documentation of Adverse Events', '48', '13.1.1.4', 'Adverse Event Severity', '49', '13.1.1.5', 'Adverse Event Causality', '49', '13.1.1.6', 'Study Drug Action Taken', '50', '13.1.1.7', 'Adverse Event Outcome', '50', '13.1.1.8', 'Treatment Given', '50', '13.1.2', 'Serious Adverse Events', '51', '13.1.2.1', 'Definition of a Serious Adverse Event', '51', '13.1.2.2', 'Reporting and Documentation of Serious Adverse Events', '51', '13.1.2.3', 'Expedited Reporting and Investigator Safety Letters', '52', '13.2', 'Administrative Requirements', '52', '13.2.1', 'Ethical Considerations', '52', '13.2.2', 'Subject Information and Informed Consent', '52', '13.2.3', 'Investigator Compliance', '53', '13.2.4', 'Access to Records', '53', '13.2.5', 'Subject Privacy', '53', '13.2.6', 'Record Retention', '53', '13.2.7', 'Study Termination', '53', '13.2.8', 'End of Study', '54', '13.3', 'Data Quality Assurance', '54', '13.4 Monitoring', '54', '13.5 Electronic Data Capture', '54', '13.6 Confidentiality and Disclosure', '55', '13.7 Publications and Clinical Study Report', '55', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}